30 closest matches · ranked by relevance
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
Cryptococcal Meningitis
Primary: Early Fungicidal Activity — 0.39; 0.28 log10 CFU/mL/day
Cryptococcal Meningitis
Primary: Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug — 2; 1; 0; 0 Events
Cryptococcal Meningitis · HIV Infections · AIDS
Primary: Mortality — 40; 27 participants — p=0.03
Cryptococcal Meningitis · Fungal Meningitis
Primary: Survival — 125; 109 Participants
Candidiasis, Chronic Mucocutaneous
Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Candidiasis
Primary: Death or Candidiasis — 31; 37 participants
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
Invasive Candidiasis
Primary: Number of Patients Who Develop Significant Drug-related Adverse Events. — 2; 3 Participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Invasive Fungal Infection — 3; 4; 2 participants
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Candidiasis, Invasive · Candidemia · Mycoses
Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Neoplastic Meningitis
Primary: Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells — 93 percentage of participants
Coccidioidomycosis
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A — 5; 3…
Vulvovaginitis · Yeast Infection · Yeast Infection Vaginal
Primary: Clinical Outcome Assessed at Test of Cure Visit — 13; 12; 24; 12 Participants
Invasive Aspergillosis
Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…
Candidemia
Primary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition
Invasive Fungal Disease
Primary: Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) — 7.9; 11.7 percentage of…
Lymphoma · Infection · Leukemia
Primary: Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant — 74.9; 78.2…
Fungal Infection · Hematopoietic and Lymphoid Cell Neoplasm
Primary: 42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections (IFI) — 1.4; 1.4 percentage of patients
Invasive Fungal Infections · Hematologic Malignancies
Primary: Incidence of Invasive Fungal Infection (IFI) — 0; 5 percentage of participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Leukopenia
Primary: Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period — 4; 11 participants
Possible Fungal Infection
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis — 6; 9 participants — p=0.258
Candidemia · Mycoses · Fungal Infection
Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants